Experimental drugs and therapies are flourishing in China, and patients who feel they have little to lose are flocking there to try them, according to an article in the Asia Times, which references a study published in Nature Biotechnology. Click here to read. One of the players? China's Beike Biotechnologies, which reportedly harvests stem cells from the umbilical cord or amniotic membrane and injects them into patient's spinal region. More than 1,000 patients, including 60 foreigners, have been treated for a variety of conditions, the article says. China also has the world's first commercialized gene therapy, Gendicine, and is manufacturing one of the only two oral cholera vaccines available.